Mission
To develop and provide diagnosis products and metabolomic services aiming to contribute to the progression of knowledge, prevention, diagnosis and treatment of complex diseases submitted to research on the company.
Vision
To be the best-in class performer in metabolomics and its application in the development of diagnostic systems for highly prevalent complex diseases in Europe and worldwide.
Strategy
The activity of the company is centered in the area of human health and its objective is to identify, validate, patent and commercialize early diagnostic and/or prognostic systems, as well as therapeutic targets implied in the development of hepatic diseases and other great prevalence complex pathologies. To accomplish this we use innovative technology in genomics, proteomics, metabolomics and bioinformatics and have established a complete and highly productive platform which supports the advance of our developments.
Business Lines
OWL has developed a technological platform that systematically combines innovative technology in genomics, proteomics, metabolomics and bioinformatics with the aim of developing early diagnosis systems, searching therapeutic targets and providing a complete metabolomic service to external organizations.
Currently there are two business lines:
- In vitro serum based diagnosis products:
- owl liver: owl liver is the first serum based test to be used for Steatosis and NASH diagnosis. It is an innovative non-invasive method that allows the diagnosis through the identification and validation of metabolomic biomarkers.
- Product Pipeline: OWL is currently applying its know-how in metabolomic technology to other diseases with complex diagnostics with a personalized medicine approach..
- Metabolomics Servicies to external organizations: OWL offers metabolomic services to pharmaceutical and biotechnology companies in key areas such as biomarkers discovery, clinical studies, diagnostics and toxicology.
OWL strives to provide a top quality service for cutting-edge research, using strictly controlled analytical procedures and state of the art facilities under expert supervision.
- From a multi-technological approach, becoming a leader in metabolomics.
- Applying this technology not only to hepatic diseases but also to other complex pathologies.
- Going from biotechnological research to commercialize new products and services.